The ARTAS robotic hair transplant system entered clinical use in 2011 with a compelling pitch: a robotic arm equipped with imaging guidance and precision engineering could perform follicular unit extraction more consistently than human hands. Consistency in FUE, the individual extraction of follicular units from the donor area without a linear incision, matters because transection rate (the percentage of follicles damaged during extraction) is the primary driver of graft survival and ultimately transplant outcome. Skilled human operators achieve transection rates of 3–8%. The question was whether robotics could do better, and whether that translated to patient outcomes.

The ARTAS consortium study published in Plastic and Reconstructive Surgery in March 2025 is the most methodologically robust comparison to date: 800 patients across 12 sites randomised to ARTAS robotic FUE or experienced manual FUE operator, with blinded graft assessment and 12-month follow-up. The comparison was between ARTAS and surgeons with at least 1,000 prior manual FUE cases, the appropriate comparator, since you shouldn't compare a robot to a novice.

The primary outcome, graft transection rate, showed a modest but statistically significant advantage for ARTAS: 3.8% versus 5.1% for manual in the pooled analysis. That's a real difference. Fewer damaged grafts per extraction means more viable follicles available for transplantation. The clinical significance in terms of patient outcomes is where the study gets more interesting. At 12 months, hair density at the recipient site, measured by trichoscopy and global photography rating, showed no statistically significant difference between the two groups. The transection rate advantage of robotics translated to more viable grafts in the dish, but not to meaningfully better hair density outcomes in the recipient area.

Several confounding factors explain this gap. Graft survival after transplantation depends not only on extraction quality but on the skill of graft handling, storage, and implantation, none of which the robotic system affects. A 1.3% advantage in transection rate is essentially washed out by the variability in these subsequent steps, all of which remain manual. The robotic system's speed is also lower than an experienced manual operator: ARTAS in its current configuration can extract approximately 500 grafts per hour versus 800–1,000 for skilled manual FUE, meaning longer surgical sessions for the same number of grafts.

The study does not suggest robotics is worse than manual FUE, the outcomes are equivalent. But it challenges the premium pricing justified by better results that many clinics attach to robotic procedures. The ARTAS system adds approximately £2,000–£4,000 to procedure cost in UK practice. If outcomes are equivalent to skilled manual FUE, that premium isn't supported by clinical evidence.

Where robotic transplantation is likely to differentiate itself meaningfully over the next five years is not in raw extraction metrics but in planning and artificial intelligence integration. The ARTAS system's imaging can now generate donor area maps and recommend extraction patterns that optimise donor density preservation, preventing the over-harvested, moth-eaten donor areas that result from poorly planned manual FUE. As the AI planning component matures, the robotic advantage may end up being less about the extraction mechanics and more about the intelligence of the planning that precedes it.